A Randomized Phase Ii Study Of Erdafitinib (Erda) Versus Intravesical Chemotherapy (Ic) In Patients With High-Risk Nonmuscle Invasive Bladder Cancer (Hr-Nmibc) With Fgfr Mutations Or Fusions, Who Recurred After Bacillus Calmette-Guerin (Bcg) Therapy

Gary D. Steinberg,Joan Palou-Redorta,Juergen E. Gschwend,Ben Tran,Yohann Loriot,Siamak Daneshmand,Morgan Roupret,Ademi E. Santiago-Walker, Julie C. Switzky,Christopher Major,Mahadi Baig,Qi Xia,James Wf Catto

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 12|浏览12

暂无评分

摘要

TPS603Background: ERDA, an oral pan-FGFR inhibitor, is approved by the US FDA for metastatic urothelial carcinoma (mUC) with susceptible FGFR3 or FGFR2 gene alterations and progressed on/ or after ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要